The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Inclusion Criteria

• •Adults, 18 years or older with histologically confirmed metastatic pancreatic ductal adenocarcinoma or poorly differentiated carcinoma.
• •Measurable disease according to RECIST 1.1.
• •Archival tumour tissue for tertiary correlative studies (biopsy or resection of primary or metastasis). Fine needle aspirate (FNA) or brushings will not be accepted.
• •ECOG performance of 0-1 (Appendix 2)
• •Adequate renal and haematological function
• •Adequate hepatic function, defined as:
• •Bilirubin \<1.5 X ULN (Upper Limit of Normal), AST or ALT ≤ 5x ULN. If a person was recently stented with improving bilirubin, the person can be randomised with bilirubin up to 3 x ULN provided chemotherapy is not administered until within the stated thresholds.
• •Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments.
• •Study treatment both planned and able to start within 7 days after randomisation
• •Signed, written informed consent.
• •Concurrent use of any other anti-cancer therapy including chemotherapy, targeted therapy, immunotherapy or biological agents.
• •Known allergy or hypersensitivity to any of the study drugs and excipients.
• •Any significant active infection, including chronic active hepatitis B, hepatitis C, or HIV. Participants with known Hepatitis B/C infection will be allowed to participate providing evidence of viral suppression has been documented and the patient remains on appropriate anti-viral therapy.
• •History of prior or synchronous malignancy within 2 years prior to randomisation, except:
• •1. Malignancy that was treated with curative intent and for which there has been no known active disease for ≥2 years prior to randomisation.
• •2. Curatively treated non-melanoma skin cancer, cervical cancer in situ, superficial transitional cell carcinoma of the bladder, stage 1 endometrial carcinoma, prostatic intraepithelial neoplasia, low-grade papillary thyroid cancer, untreated localised very low risk or low risk prostate cancer under observation.
• •Concurrent illness, including severe infection that may jeopardise the ability of the person to undergo the procedures outlined in this protocol with reasonable safety.
• •Neuroendocrine pancreatic carcinoma.
• •Life expectancy of less than 3 months.
• •Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to randomisation. Men must use a reliable means of contraception.
• •Serious medical or psychiatric conditions that might limit the ability of the person to comply with the protocol.